J Biomed Nanotechnol. 2020 Apr 1;16(4):446-455. doi: 10.1166/jbn.2020.2834.
To assess AB-BEZ235-NP potential as a radio-sensitizer in hepatocellular carcinoma models.
By comparing hepatocellular carcinoma cell with simple radiation or combined AB-BEZ235-NP therapy, the HCC apoptosis and self-repair level have significant differences in mortality rates and cell migration abilities.
Cell proliferation and DNA damage increased by pretreatment with AB-BEZ235-NP after irradiation; further studies on the repair pathway indicated that AB-BEZ235-NP inhibited the important pathway of DSB repair. Our results further show that AB-BEZ235-NP significantly inhibits the phosphorylation of the canonical protein, -H2AX, in the NHEJ DSB repair pathway and Serine Protein Kinase (SPK) ATM, and TP53-Binding Protein one. More importantly, AB-BEZ235-NP increased the mount of mean -H2AX Foci in irradiated cells, indicating that AB-BEZ235-NP can selectively inhibit DSB repair in HCC cells. Therefore, these results clearly eludicate that treatment with AB-BEZ235-NP is a potential promising therapy which can increase the radiosensitivity to HCC.
评估 AB-BEZ235-NP 作为肝癌模型放射增敏剂的潜力。
通过比较肝癌细胞单纯放射治疗或联合 AB-BEZ235-NP 治疗,在死亡率和细胞迁移能力方面,肝癌细胞的凋亡和自我修复水平有显著差异。
AB-BEZ235-NP 预处理后照射可增加细胞增殖和 DNA 损伤;对修复途径的进一步研究表明,AB-BEZ235-NP 抑制了 DSB 修复的重要途径。我们的结果进一步表明,AB-BEZ235-NP 显著抑制了非同源末端连接(NHEJ)DSB 修复途径中经典蛋白 -H2AX 和丝氨酸蛋白激酶(SPK)ATM、TP53 结合蛋白 1 的磷酸化。更重要的是,AB-BEZ235-NP 增加了照射细胞中平均 -H2AX 焦点的数量,表明 AB-BEZ235-NP 可以选择性抑制 HCC 细胞中的 DSB 修复。因此,这些结果清楚地阐明,AB-BEZ235-NP 治疗是一种有潜力的治疗方法,可以提高 HCC 的放射敏感性。